Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database
Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database
复制标题
DOI：
10.1016/j.urology.2004.11.005
复制
发表时间：
2005-04-01
期刊：
影响因子：
2.1
通讯作者：
Patard, JJ
中科院分区：
文献类型：
--
作者：
Cindolo, L;De la Taille, A;Patard, JJ
目标.为了分析嫌色细胞肾细胞癌（CRCC）的临床表现，我们回顾性评估了来自欧洲6个中心的数据。1985年，CRCC被确定为一种新的RCC组织学亚型。由于其频率低，只有少数大型CRCC系列可用。我们建立了一个肾癌数据库，包括1986年至2002年在欧洲6个中心接受手术的3228例患者。从每个机构的临床图表中提取相关的临床和病理数据，并收集到一个独特的数据库中。在3228例患者中，确定了104例（3.2%）受CRCC影响。诊断时的平均年龄为57.6岁（范围22至83岁）。在104例患者中，51例（49%）为男性，53例（51%）为女性。平均肿瘤大小为6.4 ± 3.6 cm。偶然诊断占61.5%。根治性肾切除术88例（85%）。中位随访38个月（平均44个月，范围1至153）后，未观察到局部复发。CRCC的5年总生存率为81%。104例患者中，5例（4.8%）死于非相关原因，9例（8.6%）死于肾癌。我们的系列研究证实了CRCC亚型的良好结局，局部侵袭性小，进展和癌症死亡倾向低。(c)2005年爱思唯尔公司
Objectives. To analyze the clinical behavior of chromophobe renal cell carcinoma (CRCC), we retrospectively evaluated the data from six European centers. In 1985, CRCC was identified as a new RCC histologic subtype. Because of its low frequency, only few large CRCC series are available.Methods. We created a renal cancer database including 3228 patients who underwent surgery between 1986 and 2002 in six European centers. The relevant clinical and pathologic data were extracted from the clinical charts at each institution and collected into a unique database.Results. Of the 3228 patients, 104 (3.2%) affected by CRCC were identified. The mean age at diagnosis was 57.6 years (range 22 to 83). Of the 104 patients, 51 (49%) were men and 53 (51%) were women. The mean tumor size was 6.4 +/- 3.6 cm. An incidental diagnosis accounted for 61.5% of the cases. Radical nephrectomy was performed in 88 patients (85%). After a median follow-up of 38 months (mean 44, range 1 to 153), no local recurrence was observed. The 5-year overall survival rate for CRCC was 81%. Of the 104 patients, 5 (4.8%) and 9 (8.6%) died of unrelated causes and renal cancer, respectively.Conclusions. Our series confirmed a favorable outcome for the CRCC subtype with little local aggressiveness and a low propensity for progression and death from cancer. (c) 2005 Elsevier Inc.